Researchers are working around the world and around the clock to ensure that we can stymie the spread and harm from COVID-19. Today, a new clinical study run by the Montreal Heart Institute will look at the effectiveness of saving those already infected by using a well-tested drug that holds back inflammation in patients. The body’s response to COVID-19 is runaway inflammation, which makes it one of the causes of death. This study is one of many clinical trials and studies being run right now to figure out the best way to help those with COVID-19, I chose to post this one as many readers are based in Canada and can participate in this study.
The clinical study, named COLCORONA, coordinated by the Montreal Health Innovations Coordinating Center (MHICC) is funded by the Government of Quebec and supported by Pharmascience and CGI.
COLCORONA will evaluate the phenomenon of major inflammatory storm present in adults suffering from severe complications related to COVID-19. The researchers hypothesized that the treatment could reduce the complications associated with COVID-19. The clinical study will involve the recruitment of approximately 6,000 participants followed for 30 days. Initial results will be available a few days after study completion.
Participants eligibility criteria:
- Be tested positive for COVID-19;
- Be 40 years and over;
- Not hospitalized;
- Be willing to take the drug or placebo daily for 30 days;
- Be willing to participate in two follow-up calls by phone or videoconference.